查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951808

核子醫學市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、最終用戶、設備、流程、模式、安裝類型

Nuclear Medicine Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Process, Mode, Installation Type
出版日期: | 出版商: Global Insight Services | 英文 332 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計核醫市場規模將從2024年的173億美元成長到2034年的494億美元，複合年成長率約為11.8%。核子醫學市場涵蓋使用放射性物質的診斷和治療應用，包括放射性藥物、影像設備以及利用原子核特性進行精準醫療的服務。市場成長的驅動力包括影像技術的進步、慢性病發病率的上升以及對非侵入性診斷技術日益成長的需求。標靶放射性核素治療的創新和監管核准正在推動市場進一步成長，為改善患者預後和製定個人化治療策略提供了機會。

核子醫學市場正經歷強勁成長，這主要得益於診斷成像技術和標靶治療技術的進步。診斷領域成長最為迅猛，主要得益於SPECT和PET成像技術的日益普及。這些影像方式對於精準的疾病診斷和治療方案製定至關重要。治療領域緊隨其後，用於腫瘤治療的放射性藥物因其定向和療效而備受關注。在診斷領域，PET成像有望憑藉主導地位。 SPECT成像憑藉其成本效益和廣泛的應用，繼續保持第二大細分市場的強勁表現。在治療領域，針對前列腺癌和神經內分泌腫瘤的放射性藥物有望成為未來成長的主要驅動力，這反映了個人化醫療的進步。此外，人工智慧在核子醫學領域的應用有望提高診斷準確性和營運效率，從而進一步推動市場擴張。

市場區隔
類型 用於診斷和治療
產品 放射性藥物、核子醫學設備
服務 放射性同位素生產、迴旋加速器服務、放射性藥物製備、諮詢服務
科技 PET、SPECT、α發射體、BETA發射體、γ發射體
應用領域 腫瘤科、心臟科、神經科、內分泌科、消化科、整形外科
最終用戶 醫院、診斷中心、實驗室
裝置 PET掃描器、SPECT掃描器、伽馬攝影機
過程 影像診斷、治療
模式 體內、體外
安裝類型 固定式，移動式

核子醫學市場正經歷顯著的發展，這主要得益於競爭格局的加劇以及各種新產品的推出。定價策略和創新產品的推出正日益影響市場佔有率，重塑消費者的偏好，並推動市場需求。隨著各公司致力於提升核醫學技術的有效性和準確性，預計市場將實現顯著成長。主要企業正策略性地部署其產品，以抓住新的機遇，尤其是在醫療保健投資較高的地區。核子醫學領域的競爭異常激烈，主要企業積極將自身產品與競爭對手的產品進行比較，以保持競爭優勢。監管具有重要影響，北美和歐洲的嚴格指導方針塑造了營運標準。這些監管規定與技術進步相結合，對市場動態的形成至關重要。該行業的特點是創新與合規之間的密切互動，推動著市場的發展演變。不斷完善的法規結構為尋求利用最尖端科技的市場參與企業帶來了挑戰和機會。

主要趨勢和促進因素：

核子醫學市場正經歷強勁成長，這主要得益於診斷影像技術和治療應用的進步。人工智慧（AI）與影像技術的融合是關鍵趨勢，它提高了疾病檢測和治療方案製定的準確性和效率。新型放射性藥物的研發拓展了核子醫學的應用範圍，並為標靶治療開闢了新的途徑。推動該市場成長的因素包括癌症和心血管疾病等慢性病的盛行率上升，這些疾病需要先進的診斷和治療解決方案。全球人口老化進一步推動了對核醫學的需求，因為老年人更容易患上這些疾病。監管支持和研發投入的增加也是市場擴張的關鍵促進因素。此外，個人化醫療的日益普及正在推動核醫學的創新，並為精準診斷和治療創造了機會。在新興市場，醫療基礎設施的改善和公眾意識的提高為市場擴張提供了廣闊的前景。投資研發和合作的公司能夠更好地掌握這些趨勢，從而促進核醫市場的持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 診斷
    • 治療
  • 市場規模及預測：依產品分類
    • 放射性藥物
    • 核子醫學設備
  • 市場規模及預測：依服務分類
    • 放射性同位素的生產
    • 迴旋加速器服務
    • 放射性藥物
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • PET
    • SPECT
    • 阿爾法發射體
    • BETA射線放射體
    • 伽瑪射線發射體
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 內分泌學
    • 胃腸病學
    • 整形外科
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷中心
    • 研究所
  • 市場規模及預測：依設備分類
    • PET掃描儀
    • SPECT掃描儀
    • 伽馬攝影機
  • 市場規模及預測：依製程分類
    • 影像診斷
    • 治療方法
  • 市場規模及預測：按模式
    • In vivo
    • 體外
  • 市場規模及預測：依安裝類型分類
    • 固定的
    • 移動的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Curium
  • Sofie Biosciences
  • Advanced Accelerator Applications
  • Blue Earth Diagnostics
  • Radiomedix
  • Isologic Innovative Radiopharmaceuticals
  • North Star Medical Radioisotopes
  • Jubilant Radiopharma
  • Shine Medical Technologies
  • Cyclopharm
  • Immunomedics
  • Progenics Pharmaceuticals
  • Lantheus Holdings
  • ITM Isotope Technologies Munich
  • Telix Pharmaceuticals
  • Eckert Ziegler
  • Navidea Biopharmaceuticals
  • Cardinal Health Nuclear Pharmacy Services
  • NTP Radioisotopes
  • BWX Technologies

第9章：關於我們

簡介目錄
Product Code: GIS32423

Nuclear Medicine Market is anticipated to expand from $17.3 billion in 2024 to $49.4 billion by 2034, growing at a CAGR of approximately 11.8%. The Nuclear Medicine Market encompasses diagnostic and therapeutic applications using radioactive substances. It includes radiopharmaceuticals, imaging devices, and services that leverage nuclear properties for precision medicine. This market is driven by advancements in imaging technologies, increasing prevalence of chronic diseases, and the rising demand for non-invasive diagnostic techniques. Innovations in targeted radionuclide therapy and regulatory approvals are further propelling growth, offering opportunities for enhanced patient outcomes and personalized treatment strategies.

The Nuclear Medicine Market is experiencing robust growth, propelled by advancements in diagnostic imaging and targeted therapeutic techniques. The diagnostic segment is the top performer, primarily driven by the increasing adoption of SPECT and PET imaging technologies. These modalities are essential for precise disease diagnosis and treatment planning. The therapeutic segment follows closely, with radiopharmaceuticals for oncology applications gaining significant traction due to their targeted approach and efficacy. Within the diagnostic sub-segment, PET imaging is expected to maintain its leading position, supported by ongoing technological enhancements and expanding clinical applications. SPECT imaging, as the second-highest performing sub-segment, benefits from its cost-effectiveness and widespread availability. In the therapeutic sub-segment, radiopharmaceuticals targeting prostate cancer and neuroendocrine tumors are anticipated to drive future growth, reflecting advancements in personalized medicine. Additionally, the integration of artificial intelligence in nuclear medicine is poised to enhance diagnostic accuracy and operational efficiency, further fueling market expansion.

Market Segmentation
TypeDiagnostic, Therapeutic
ProductRadiopharmaceuticals, Nuclear Medicine Equipment
ServicesRadioisotope Production, Cyclotron Services, Radiopharmacy, Consultation Services
TechnologyPET, SPECT, Alpha Emitters, Beta Emitters, Gamma Emitters
ApplicationOncology, Cardiology, Neurology, Endocrinology, Gastroenterology, Orthopedics
End UserHospitals, Diagnostic Centers, Research Institutes
DevicePET Scanners, SPECT Scanners, Gamma Cameras
ProcessImaging, Therapy
ModeIn Vivo, In Vitro
Installation TypeFixed, Mobile

The Nuclear Medicine Market is witnessing significant advancements with a diverse range of new product launches enhancing its competitive landscape. Market share is increasingly influenced by pricing strategies and innovative product introductions, which are reshaping consumer preferences and driving demand. As companies focus on enhancing the efficacy and precision of nuclear medicine technologies, the market is poised for substantial growth. Key players are strategically positioning their offerings to capture emerging opportunities, particularly in regions demonstrating heightened healthcare investments. Competition within the nuclear medicine sector is intense, with key players actively benchmarking their offerings against rivals to maintain a competitive edge. Regulatory influences are substantial, with stringent guidelines in North America and Europe shaping operational standards. These regulations, coupled with technological advancements, are pivotal in defining market dynamics. The landscape is characterized by a robust interplay of innovation and compliance, driving market evolution. As regulatory frameworks evolve, they present both challenges and opportunities for market participants seeking to leverage cutting-edge technologies.

Geographical Overview:

The nuclear medicine market is witnessing substantial growth across various regions, each demonstrating unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and significant investments in research and development. The region's emphasis on innovation and early adoption of new technologies further propels market growth. Europe follows suit, with robust healthcare systems and a strong focus on precision medicine enhancing its market potential. The Asia Pacific region is emerging as a lucrative growth pocket, fueled by increasing healthcare expenditure and rising awareness about nuclear medicine's benefits. Countries like China and India are at the forefront, investing heavily in healthcare infrastructure and research initiatives. Latin America, with countries such as Brazil, is also showing promise, driven by improving healthcare access and growing demand for advanced diagnostic techniques. Meanwhile, the Middle East & Africa are gradually recognizing the potential of nuclear medicine, with investments in healthcare modernization and infrastructure development gaining momentum.

The Nuclear Medicine Market faces complex challenges from global tariffs and geopolitical risks, particularly in East Asia. Japan and South Korea are advancing domestic production capabilities to mitigate reliance on imports amid trade tensions. China is enhancing its nuclear medicine infrastructure, focusing on self-sufficiency and innovation to counteract potential supply chain disruptions. Taiwan, with its strategic semiconductor industry, is pivotal yet vulnerable to geopolitical strains. Globally, the nuclear medicine sector is expanding, driven by technological advancements and rising healthcare demands. By 2035, market evolution will hinge on robust regional collaborations and supply chain resilience. Concurrently, Middle East conflicts could escalate energy prices, indirectly affecting production costs and logistics in the nuclear medicine domain, necessitating strategic energy sourcing and risk management.

Key Trends and Drivers:

The nuclear medicine market is experiencing robust growth, propelled by advancements in diagnostic imaging and therapeutic applications. Key trends include the integration of artificial intelligence in imaging technologies, enhancing accuracy and efficiency in disease detection and treatment planning. The development of novel radiopharmaceuticals is expanding the scope of nuclear medicine, offering new avenues for targeted therapies. Drivers of this market include the rising prevalence of chronic diseases such as cancer and cardiovascular disorders, necessitating advanced diagnostic and treatment solutions. The aging global population further fuels demand for nuclear medicine, as older adults are more susceptible to these conditions. Regulatory support and increased funding for research and development are also significant contributors to market expansion. Additionally, the growing adoption of personalized medicine is fostering innovation in nuclear medicine, with opportunities in precision diagnostics and therapeutics. Emerging markets present lucrative opportunities for expansion, driven by increasing healthcare infrastructure and awareness. Companies investing in research and collaborations are well-positioned to capitalize on these trends, ensuring sustained growth in the nuclear medicine market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode
  • 2.10 Key Market Highlights by Installation Type

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostic
    • 4.1.2 Therapeutic
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Radiopharmaceuticals
    • 4.2.2 Nuclear Medicine Equipment
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Radioisotope Production
    • 4.3.2 Cyclotron Services
    • 4.3.3 Radiopharmacy
    • 4.3.4 Consultation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 PET
    • 4.4.2 SPECT
    • 4.4.3 Alpha Emitters
    • 4.4.4 Beta Emitters
    • 4.4.5 Gamma Emitters
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiology
    • 4.5.3 Neurology
    • 4.5.4 Endocrinology
    • 4.5.5 Gastroenterology
    • 4.5.6 Orthopedics
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Centers
    • 4.6.3 Research Institutes
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 PET Scanners
    • 4.7.2 SPECT Scanners
    • 4.7.3 Gamma Cameras
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Imaging
    • 4.8.2 Therapy
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 In Vivo
    • 4.9.2 In Vitro
  • 4.10 Market Size & Forecast by Installation Type (2020-2035)
    • 4.10.1 Fixed
    • 4.10.2 Mobile

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
      • 5.2.1.10 Installation Type
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
      • 5.2.2.10 Installation Type
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
      • 5.2.3.10 Installation Type
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
      • 5.3.1.10 Installation Type
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
      • 5.3.2.10 Installation Type
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
      • 5.3.3.10 Installation Type
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
      • 5.4.1.10 Installation Type
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
      • 5.4.2.10 Installation Type
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
      • 5.4.3.10 Installation Type
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
      • 5.4.4.10 Installation Type
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
      • 5.4.5.10 Installation Type
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
      • 5.4.6.10 Installation Type
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
      • 5.4.7.10 Installation Type
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
      • 5.5.1.10 Installation Type
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
      • 5.5.2.10 Installation Type
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
      • 5.5.3.10 Installation Type
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
      • 5.5.4.10 Installation Type
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
      • 5.5.5.10 Installation Type
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
      • 5.5.6.10 Installation Type
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
      • 5.6.1.10 Installation Type
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
      • 5.6.2.10 Installation Type
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
      • 5.6.3.10 Installation Type
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
      • 5.6.4.10 Installation Type
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 Mode
      • 5.6.5.10 Installation Type

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Curium
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sofie Biosciences
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Advanced Accelerator Applications
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Blue Earth Diagnostics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Radiomedix
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Isologic Innovative Radiopharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 North Star Medical Radioisotopes
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Jubilant Radiopharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Shine Medical Technologies
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cyclopharm
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immunomedics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Progenics Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Lantheus Holdings
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 ITM Isotope Technologies Munich
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Telix Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Eckert Ziegler
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Navidea Biopharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cardinal Health Nuclear Pharmacy Services
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 NTP Radioisotopes
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 BWX Technologies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us